flubendazole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Fu, L; Fu, Y; Liu, Y; Yuan, Z; Zhang, J; Zhang, L; Zhen, Y; Zhou, XL | 1 |
| Fu, L; Gao, F; Jiang, X; Wang, M; Zhang, L; Zhao, R; Zhen, Y; Zhou, XL | 1 |
2 other study(ies) available for flubendazole and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer.
Topics: Dynamins; Humans; Mebendazole; Mitochondria; Mitophagy; Triple Negative Breast Neoplasms; Ubiquitin-Protein Ligases | 2022 |
Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Drug Repositioning; Female; Humans; Mebendazole; Membrane Proteins; Mice; Molecular Docking Simulation; Mutagenesis, Site-Directed; Protein Binding; RNA-Seq; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |